All News
Evaluation of Bimekizumab in PsA
Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A and F. There have been more updates on the 2 year data on BKZ at #ACR24, and this is a summary of four studies being presented this year at ACR24.
Read Article
ACR24 Preview Podcast (11.15.2024)
ACR 2024 starts tomorrow. Here are a few previews of abstracts to be presented, along with my recommendations of sessions you don’t want to miss.
Read Article
Biosimilar Slow Growth in USA
A recent Forbes article, "Biosimilars Are Making Inroads In U.S., But It’s Still A Bumpy Ride", reviews the current state and reasons for slowish uptake of these significant cost-savings alternatives to biologic therapy in treating cancer and autoimmune disorders. The following are takeaway bullets from this informative article.
Read Article
Dr. Quotes (11.8.2024)
Dr. Jack Cush reviews the news and journal reports from this past week from RheumNow.com.
Read Article
Advances in the treatment of autoimmune hepatitis
EurekAlert!
Autoimmune hepatitis (AIH) is a chronic, progressive liver disease caused by immune system dysregulation that targets the liver. If untreated, AIH can lead to severe complications, including cirrhosis and liver failure.
Read Article
Cool data from the JAK-POT study
Have heard JAKs faster than TNF; perhaps not the case!
If anything, TNFs outperformed the others in this study
Trying not to over-read this, but supports my re-emerging preference for TNF
#ACR24 @rheumnow Abstr#0501 https://t.co/NDyPwju3ds
Links:
Mike Putman EBRheum ( View Tweet)
🤨To cycle or not to cycle TNFi. Abst#0585 studied pts with PsA and axSpA with primary TNFi failure:
-Switching to IL17Ai may benefit phGA for arthritis and psoriasis in PsA pts and fatigue in axSpA pts. @AlexisOgdie
#ACR24 @RheumNow https://t.co/Jc0cdmrVhI
Adela Castro AdelaCastro222 ( View Tweet)
#0501
💥 JAKi & TNFi show faster short-term RA improvement (3months) compared to IL-6i & ABA
➡️n=9590(3049 JAKi, 4606 TNFi, 1284 IL-6, 651 ABA), 14 registers
🕒 JAKi, TNFi improved CDAI, pain, function in 1st two months then stabilised
💡Long-term data needed #ACR24 @RheumNow https://t.co/4yzeAAkGjq
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
TNFi cycling vs. switching to IL-17Ai?
Dr @AlexisOgdie et al from CorEvitas registry:
PsA & axSpA cohort - switchers (TNFi to IL17i) had greater improvements in cDAPSA & BASDAI vs. cyclers (2nd TNF)
Not stat significant but offers alternative Tx options
@RheumNow #ACR24 abs585 https://t.co/8m347BRM75
sheila RHEUMarampa ( View Tweet)
#obesity causes a lot of diseases including #arthritis. How?
⬆️ IL-6
⬆️ leptin
⬆️ TNF-a
@RheumNow #ACR24
@rheumarhyme https://t.co/qeqTZUOEZy
sheila RHEUMarampa ( View Tweet)
What agent to pick after a TNFi has failed: another TNFi or a non-TNFi?
Would a TNFi drug conc help (i.e. if low, increased clearance due to secondary failure)?
In this RCT @maartenskliniek, this TDM approach was no better than random selection. Argh
#ACR24 ABST0533 @RheumNow https://t.co/3h8o4ARZG3
David Liew drdavidliew ( View Tweet)
Real-world data from @k_lauper's Jak-pot study (>9000 RA pt) on how quickly b/tsDMARDs work:
JAKi, TNFi quicker than tocilizumab, abatacept
Even though they all get to a similar place eventually, some get there quicker
(but worth any safety tradeoffs?)
#ACR24 ABST0501 @RheumNow https://t.co/YVpTBMe3gi
David Liew drdavidliew ( View Tweet)
RA pearls from #ACR24 review course:
1. Remission is DRUG maintained-Ok to reduce MTX dose while on TNFi.
2. Multimorbidity=Poor outcomes, High risk for mortality.
3. Can RA be truly prevented or we are delaying the inevitable? https://t.co/111w1Myqrg
Links:
Adela Castro AdelaCastro222 ( View Tweet)
No Increase in Cardiovascular Events with JAK Inhibitors in IBD Patients
UMKC researchers have compared the use of JAK inhibitors versus tumor necrosis factor (TNF) blockers in inflammatory bowel disease (IBD) patients, but failed to see an increase in major adverse… https://t.co/XY0UVDTAI6 https://t.co/b09FB3niNP
Dr. John Cush RheumNow ( View Tweet)
Save the date! RheumNows will be covering #ACR24 from 11/14-11/19. Get ready for daily recaps, live streaming and much, much, more! https://t.co/vwNFU501di
Dr. John Cush RheumNow ( View Tweet)
Early Rx doesnt prevent Difficult to Tx RA (D2TRA). Propective study of 722 early RA pts Rx w/ MTX found after 73 mos 29% were D2TRA. 21.5% Rx w/ b/tsDMARD after 19 mos, yet 70% were uncontrolled. 5 yr retention rates were 40%. D2T predicted by pain & swollen joints… https://t.co/veaspuCHIE https://t.co/zjlTWQn4GQ
Dr. John Cush RheumNow ( View Tweet)
Korean database of 43,502 #AS pts found CV events based on Rx exposure. CV event rates were: No bDMARDS (18.66/10K PYs), TNFi (8.92), & IL-17i (12.87). TNFi significantly lowered rate of CVE (aHR 0.69), but IL-17i did not (0.96) https://t.co/LMzPodWI5v https://t.co/rQ0aq1ALgW
Dr. John Cush RheumNow ( View Tweet)
Overview of Uveitis management of adult & pediatric rheumatology.
- Uveitis accounts for 10% of visual impairment globally
- TNF inhib are effective; w/ IL-6 inhib as 2nd line options https://t.co/CmGuA7W4Ag https://t.co/p5aEQlV7p6
Dr. John Cush RheumNow ( View Tweet)
Save the date! RheumNow will be covering #ACR24 from 11/14-11/19. Get ready for daily recaps, live streaming and much, much, more! https://t.co/rDMFH3wlbc
Dr. John Cush RheumNow ( View Tweet)
Overview of IL-23 inhibition for chronic inflammatory disease (partial read) from Lancet. Started with targeting the p40 subunit shared between IL-12 & IL-23A. Now we have specific inhibitors of the p19 protein of IL-23A. These agents are superior to TNFi in plaque… https://t.co/ud61WLgWs2 https://t.co/fQ7WhLyrsi
Dr. John Cush RheumNow ( View Tweet)
